TALICIA
Peakomeprazole magnesium, amoxicillin and rifabutin
NDAORALCAPSULE, DELAYED RELEASEPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALICIA is a fixed-dose oral combination capsule containing omeprazole magnesium, amoxicillin, and rifabutin, approved in November 2019 for the treatment of Helicobacter pylori infection. This triple-therapy agent works by combining a proton pump inhibitor with two antimicrobial agents to eradicate H. pylori bacteria in the stomach. The delayed-release formulation protects the active ingredients from gastric acid degradation.
$3MPart D
Peak15.9 years to LOEProduct is in peak commercial phase but with modest Part D spending ($3M annually), indicating a niche market with limited growth potential and likely smaller brand team structure.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antimycobacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TALICIA roles focus on commercial execution and market maintenance within a niche specialty segment rather than expansion-stage opportunities. Career growth is likely modest given the product's peak-phase status, limited market size ($3M spending), and absence of active clinical development.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.